105 L. M. L. de Lau et al., “Serum cholesterol levels and the risk of Parkinson’s disease.” American Journal of Epidemiology 164, no. 10 (November 2006): 998–1002.

106 L. Dupuis et al., “Dyslipidemia is a protective factor in amyotrophic lateral sclerosis.” Neurology 70, no. 13 (March 2008): 1004–9.

107 X. Huang et al., “Low LDL cholesterol and increased risk of Parkinson’s disease: prospective results from Honolulu-Asia Aging Study.” Movement Disorders: Official Journal of the Movement Disorder Society 23, no. 7 (May 2008): 1013–18.

108 D. S. Ng et al., “HDL – is it too big to fail?” Nature Reviews Endocrinology 9, no. 5 (May 2013): 308–12.

109 N. Barzilai et al., “Unique lipoprotein phenotype and genotype associated with exceptional longevity.” JAMA 290, no. 15 (October 2003): 2030–40.

110 P. W. Siri-Tarino et al., “Meta-analysis of prospective cohort studies evaluating the association of saturated fat with cardiovascular disease.” American Journal of Clinical Nutrition 91, no. 3 (March 2010): 535–46.

111 M. U. Jakobsen et al., “Major types of dietary fat and risk of coronary heart disease: a pooled analysis of 11 cohort studies.” American Journal of Clinical Nutrition 89, no. 5 (May 2009): 1425–32.

112 R. P. Mensink et al., “Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials.” American Journal of Clinical Nutrition 77, no. 5 (May 2003): 1146–55.

113 J. E. Hokanson et al., “Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies.” Journal of Cardiovascular Risk 3, no. 2 (April 1996): 213–19.

114 M. U. Jakobsen et al., “Intake of carbohydrates compared with intake of saturated fatty acids and risk of myocardial infarction: importance of the glycemic index.” American Journal of Clinical Nutrition 91, no. 6 (June 2010): 1764–68.

115 E. E. Canfora et al., “Short-chain fatty acids in control of body weight and insulin sensitivity.” Nature Reviews Endocrinology 11, no. 10 (August 2015): 577–91.

116 A. Andoh, “Physiological role of gut microbiota for maintaining human health.” Digestion 93, no. 3 (February 2016): 176–81.

117 A. Menotti et al., “Food intake patterns and 25-year mortality from coronary heart disease: cross-cultural correlations in the Seven Countries Study. The Seven Countries Study Research Group.” European Journal of Epidemiology 15, no. 6 (July 1999): 507–15.

118 C. B. Ebbeling et al., “Effects of dietary composition on energy expenditure during weight-loss maintenance.” JAMA 307, no. 24 (June 2012): 2627–34.

119 R. Estruch et al., “Primary prevention of cardiovascular disease with a Mediterranean diet.” New England Journal of Medicine 368, no. 14 (April 2013): 1279–90.

120 D. C. Wallace, “A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine.” Annual Review of Genetics 39 (January 2005): 359–407.

121 B. Bernardes de Jesus et al., “Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer.” EMBO Molecular Medicine 4, no. 8 (August 2012): 691–704.

122 G. Atzmon et al., “Evolution in health and medicine Sackler colloquium: genetic variation in human telomerase is associated with telomere length in Ashkenazi centenarians.” Proceedings of the National Academy of Sciences of the United States of America 107 Suppl (January 2010): 1710–17.

123 M. Crous-Bou et al., “Mediterranean diet and telomere length in Nurses’ Health Study: population based cohort study.” BMJ (Clinical Research Ed.) 349 (January 2014): g6674.

124 P. Sjogren et al., “Stand up for health – avoiding sedentary behaviour might lengthen your telomeres: secondary outcomes from a physical activity RCT in older people.” British Journal of Sports Medicine 48, no. 19 (September 2014): 1407–9.

125 D. Ornish et al., “Effect of comprehensive lifestyle changes on telomerase activity and telomere length in men with biopsy-proven low-risk prostate cancer: 5-year follow-up of a descriptive pilot study.” Lancet Oncology 14, no. 11 (October 2013): 1112–20.

126 C. W. Leung et al., “Soda and cell aging: associations between sugar-sweetened beverage consumption and leukocyte telomere length in healthy adults from the National Health and Nutrition Examination Surveys.” American Journal of Public Health 104, no. 12 (December 2014): 2425–31.

127 H. Holstege et al., “Somatic mutations found in the healthy blood compartment of a 115-yr-old woman demonstrate oligoclonal hematopoiesis.” Genome Research 24, no. 5 (April 2014): 733–42.

128 G. Bjelakovic et al., “Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis.” JAMA 297, no. 8 (February 2007): 842–57.

129 H. Macpherson et al., “Multivitamin-multimineral supplementation and mortality: a meta-analysis of randomized controlled trials.” American Journal of Clinical Nutrition 97, no. 2 (March 2013): 437–44.

130 H. D. Sesso et al., “Multivitamins in the prevention of cardiovascular disease in men: the Physicians’ Health Study II randomized controlled trial.” JAMA 308, no. 17 (November 2012): 1751–60.

131 D. H. Baker, “Cupric oxide should not be used as a copper supplement for either animals or humans.” Journal of Nutrition 129, no. 12 (December 1999): 2278–79.

132 G. S. Omenn, “Chemoprevention of lung cancer: the rise and demise of betacarotene.” Annual Review of Public Health 19 (January 1998): 73–99.

133 B. K. Dunn et al., “A nutrient approach to prostate cancer prevention: The Selenium and Vitamin E Cancer Prevention Trial (SELECT).” Nutrition and Cancer 62, no. 7 (January 2010): 896–918.

134 L. C. Clark et al., “Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group.” JAMA 276, no. 24 (December 1996): 1957–63.

135 A. Vogiatzoglou et al., “Vitamin B12 status and rate of brain volume loss in community-dwelling elderly.” Neurology 71, no. 11 (September 2008): 826–32.

136 G. Douaud et al., “Preventing Alzheimer’s disease-related gray matter atrophy by B-vitamin treatment.” Proceedings of the National Academy of Sciences of the United States of America 110, no. 23 (June 2013): 9523–28.

137 N. L. van der Zwaluw et al., “Results of 2-year vitamin B treatment on cognitive performance: secondary data from an RCT.” Neurology 83, no. 23 (December 2014): 2158–66.